---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014517"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:55:40.996536+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics provides update on itraconazole PK study; plans global patent filing for amorphous formulation

## Summary
- Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.
- Study is the final clinical study before NDA submission to FDA under 505(b)(2) pathway for Gorlin Syndrome BCCNS.
- New global patent application planned for proprietary amorphous itraconazole formulation; owned by Inhibitor with no royalty obligations.
- Amorphous formulation aims to enhance solubility and absorption vs. crystalline itraconazole to address variable exposure.
- Study conducted with Avior Bio in Malaysia; advancing on planned timelines and budget.

## SEC filing metadata
- accession: 0001493152-26-014517
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/0001493152-26-014517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014517
- JSON: https://secwatch.observer/filing/0001493152-26-014517.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.